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Chemotherapy-induced neutropenia (CIN) is a common and serious toxicity of cancer
chemotherapy. It can lead to febrile neutropenia (FN), which often requires patients to be
hospitalised for intravenous antibiotic therapy. Chemotherapy dose reductions or delays,
which can compromise clinical outcomes, may also result from CIN and FN. Prophylactic
use of colony-stimulating factors (CSFs) reduces the incidence, duration, and severity of
FN, and there is evidence that it helps maintain scheduled chemotherapy dose delivery. In
2006, three organisations published new or updated guidelines for the use of CSFs in cancer
treatment. Each recommends that FN risk be determined individually for each patient,
taking into account patient- and disease-specific risk factors, the chemotherapy regimen,
and treatment intent. Particular consideration should be given to patients who are X65
years old, receiving chemotherapy regimens associated with X20% risk of FN, receiving
dose-dense chemotherapy, and receiving treatment that is adjuvant, potentially curative,
or intended to prolong survival. Accordingly, oncology nurses can play an important role in
assessing and identifying patients at risk for FN before every chemotherapy cycle. There is
evidence that, regardless of practice type or size, implementing guidelines for CSF use
within a multidisciplinary team improves patient outcomes.
& 2007 Elsevier Ltd. All rights reserved.
Zusammenfassung
Die Chemotherapie-induzierten Neutropenie (CIN) stellt eine häufige und ernste
unerwünschte Wirkung einer Chemotherapie dar. Eine CIN kann eine febrile Neutropenie
zur Folge haben (FN), bei der oft eine intravenöse Antibiotikatherapie unter stationären
Bedingungen indiziert ist. Ferner kann es bei einer CIN oder FN erforderlich sein, die
Dosierung der Chemotherapeutika zu reduzieren oder die Chemotherapie zu verzögern.
Durch prophylaktische Anwendung von koloniestimulierenden Faktoren (CSF) lassen sich
Inzidenz, Dauer und Schwere einer FN verringern, und es existieren Hinweise, dass
prophylaktisch applizierte CSF die Einhaltung des Chemotherapie-Zeitplans erleichtern. Im
Jahr 2006 veröffentlichten drei Institutionen neue bzw. aktualisierte Richtlinien für die
Anwendung von CSF im Rahmen einer Krebstherapie. Diese drei Institutionen empfehlen,
das individuelle FN-Risiko des jeweiligen Patienten zu ermitteln, wobei patienten- undElsevier Ltd. All rights reserved.
6 460062; fax: +44 1786 460060.
ir.ac.uk (N. Kearney), christopher_friese@dfci.harvard.edu (C. Friese).
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ziel zu berücksichtigen sind. Besondere Vorsicht ist bei Patienten ab 65 Jahren geboten,
denen ein mit einem FN-Risiko Z 20 % assoziiertes Chemotherapie-Regime oder eine Dose-
dense-Chemotherapie verabreicht wird, sowie bei Patienten, die eine adjuvante,
potentiell kurative Behandlung oder eine Therapie erhalten, die lebensverlängernd wirken
soll. Onkologischen Pflegekräften kommt daher eine wichtige Rolle bei der Evaluation und
Identifizierung von Patienten mit erhöhtem FN-Risiko vor Beginn eines Chemotherapie-
Zyklus zu. Es existieren Hinweise darauf, dass die Anwendung von Richtlinien für die
Anwendung von CSF innerhalb eines interdisziplinären Teams zu einer Verbesserung des
Outcomes der Patienten führt, unabhängig von der Art oder der Größe der Arztpraxis.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chemotherapy-induced neutropenia (CIN), defined as an
absolute neutrophil count below 500/mm3, is a common and
serious toxicity of chemotherapy. It can lead to febrile
neutropenia (FN), which may result in life-threatening
infection (Crawford et al., 2004a). Patients with FN often
require immediate hospitalisation—which is associated with
substantial morbidity, mortality, and cost—for empiric
treatment with broad-spectrum antibiotics (Caggiano et
al., 2005; Kuderer et al., 2006). In addition, CIN and FN
often require dose reductions or treatment delays, which
can compromise long-term survival in patients with curable
cancers (Lyman and Kuderer, 2003).
The prevalence of CIN makes surveillance for FN a routine
concern of oncology nurses. Pettengell et al. (2006) recently
conducted a prospective observational study of routine
practice at 34 centres in western Europe that showed that
grade 4 CIN (defined in this study using the Common Toxicity
Criteria as absolute neutrophil count [ANC]o500/mm3)
occurred in 40% (95% confidence interval [CI], 28–53%) of
65 patients with Hodgkin lymphoma and 54% (95% CI,
47–60%) of 240 patients with non-Hodgkin lymphoma
(NHL). The rates of FN were 15% (95% CI, 8–27%) and 22%
(95% CI, 17–28%) in the two groups, respectively. A retro-
spective chart review of patients with breast cancer treated
at 16 Spanish hospitals between April and June of 2005
showed that 18% of 83 patients suffered from more than one
FN episode (Mayordomo et al., 2006). In the United States, a
prospective registry study of more than 4000 patients
treated with systemic chemotherapy for one of six major
cancer types documented that 24% of patients had CIN and
14% had FN (Crawford et al., 2004b).
These findings from community practice are important,
because most of the other data about the incidence of CIN
and FN was derived from randomised, controlled trials that
tend to exclude older patients and those with poor
performance status. Moreover, many reports on such trials
are incomplete. In a systematic review of trials in early-
stage breast cancer (ESBC) and NHL published between 1990
and 2000, Dale et al. (2003) found that 35% of articles did
not report the incidence or severity of myelotoxic effects of
chemotherapy. The data that were available were reported
using varying measures, and results for the same or similar
chemotherapy regimens varied widely. Thus, the true risk of
FN, even for commonly studied regimens, remains to be
determined.Randomised, controlled trials (Crawford et al., 1991;
Trillet-Lenoir et al., 1993; Holmes et al., 2002; Green et al.,
2003; Timmer-Bonte et al., 2005; Vogel et al., 2005) and
meta-analyses (Lyman et al., 2002; Kuderer et al., 2005)
have established that prophylactic use of granulocyte
colony-stimulating factor (G-CSF) reduces the incidence,
duration, and severity of FN. In 2005 and 2006, the American
Society of Clinical Oncology (ASCO) (Smith et al., 2006), the
European Organisation for Research and Treatment of
Cancer (EORTC) (Aapro et al., 2006), and the National
Comprehensive Cancer Network (NCCN) (Crawford et al.,
2006) published new or updated guidelines for the prophy-
lactic use of CSF. The main purposes of this article are to
introduce oncology nurses to these three sets of guidelines,
to discuss the role of nurses in the use and implementation
of these guidelines, and to review their resultant contribu-
tion to improved patient outcomes. The article first reviews
the adverse consequences of CIN and FN, and explains the
latest findings about the clinical efficacy of prophylactic
G-CSF.Why should nurses care about CIN and FN?
It has been known for 40 years that the risk of FN, and hence
the risk of life-threatening infection, increases in direct
relation to the duration and severity of neutropenia (Bodey
et al., 1966). Approximately a third of patients with FN have
a microbiologically confirmed infection (Gáytan-Martinez
et al., 2000; Cordonnier et al., 2005). In Europe, there is a
trend of significantly increased incidence of gram-negative
bacteraemias in neutropenic patients and in a trial of
empirical therapy for FN conducted by the EORTC Interna-
tional Antimicrobial Therapy Group in 2000, 12% of 341 FN
episodes were related to single-agent gram-negative bac-
teraemia, compared with 7.5% in a similar trial conducted in
1993 (p ¼ 0.05) (De Bock et al., 2001). Thanks to the
introduction of a wide range of effective anti-infectives and
CSFs, most patients who have FN usually require only short
hospitalisations and have successful outcomes (Lyman and
Kuderer, 2003). However, death associated with FN is far
from rare. According to a review of data on 20,780 CIN-
related hospitalisations in seven US states in 1999, the
inpatient mortality rate was 7% (Caggiano et al., 2005).
The rate was even higher, 10%, in a retrospective review of
6 years of data in more than 41,000 patients hospitalised
for FN in 115 US medical centres (Kuderer et al., 2006).
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ity, the death rate escalated to X21%.
Another adverse clinical consequence of FN is the
frequent need for chemotherapy dose reductions or delays.
Such deviations from the schedule reduce the relative dose
intensity (RDI)—the percentage of the planned dose
intensity (defined as the amount of drug delivered per unit
time) that is actually delivered to the patient (see example
in Figure 1). Maintaining RDI is important in increasing the
likelihood of improved overall and disease-free survival
(Budman et al., 1998; Kwak et al., 1990; Epelbaum et al.,
1990). Suboptimal RDI has been documented to be a
common problem for patients who develop FN. In the
European study by Pettengell et al. (2006), about 30% of
patients with lymphoma received an RDI p85% of what was
planned, and multivariate regression analysis showed that
the occurrence of FN in the first cycle was a predictor of low
RDI. A retrospective chart review carried out in 16 Spanish
hospitals in 2005 found that of 83 patients with breast
cancer who developed FN, 42% required one or more
chemotherapy dose reductions, 31% required one or more
chemotherapy dose delays, and 17% discontinued che-
motherapy altogether (Mayordomo et al., 2006). Another
subgroup analysis of this study was in 67 patients with
lymphoma who developed FN. Of these, 17% had dose
reductions, 24% had dose delays, and 15% discontinued
chemotherapy (López et al., 2006).
Studies of community practice in the United States have
also shown that CIN-related and FN-related dose modifica-Figure 1 Calculating relative dose intensity (Lenhart, 2005). Re
Relative dose intensity: improving cancer treatment and outcom
permission conveyed through Copyright Clearance Center, Inc.: athe
frame originally ordered by the physician and bthe patient received
ordered by the physician.tions are common in patients with ESBC (Link et al., 2001;
Lyman et al., 2003) and NHL (Picozzi et al., 2001; Lyman
et al., 2004). These observations are of concern because the
reduction of planned dose has been associated with poorer
long-term disease-free survival and overall survival in
potentially curable malignancies (Ardizzoni et al., 2005;
Bonadonna et al., 2005; Bonneterre et al., 2005; Early
Breast Cancer Trialists’ Collaborative Group, 2005). Yet in
the systematic review by Dale et al. (2003), 39% of reports
on ESBC trials and 54% of reports on NHL trials lacked data
about delivered RDI. Thus, because of incomplete reporting,
it is not possible to determine the true impact of severe and
FN on the delivered dose intensity associated with various
chemotherapy regimens.
In addition to clinical impact, the economic impact of FN
is considerable. In an early study in the United Kingdom,
consultant oncologists at six hospitals completed a detailed
questionnaire on how they would treat a patient admitted
for FN (Leese, 1993). Based on their responses, the
estimated average cost of FN was £1649 per episode in
1990/1991 prices. Hospitalisation was the largest single
factor, accounting for 62% of estimated cost, and an
additional 19% of the cost was associated with antibiotic
treatment. The predicted average length of stay, which
was 6 days, was similar in all six hospitals. Subsequently,
the cost of hospitalisation for a patient with a neutropenic
event was estimated at £2290 in 1996 prices, equivalent
to approximately £2750 in 2002 (Hackshaw et al., 2004).
More recently, in 2005, the multicenter review in Spainproduced with permission of Oncology Nursing Society, from
es, Lenhart, Oncology Nursing Forum, volume 32(4), 2005;
patient received 75% of the chemotherapy in the dose or time
69% of the chemotherapy in the dose or time frame originally
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4514 for patients with lymphoma (López et al., 2006) and
3519 for patients with breast cancer (Mayordomo et al.,
2006). The median length of hospital stay was 8 days for
patients with lymphoma and 6 days for patients with breast
cancer, and, as in the early UK study, the main drivers of the
cost of managing FN were hospitalisation and antibiotic
treatment (López et al., 2006; Mayordomo et al., 2006).
In the United States, the 1999 review of administrative
data showed that the average cost of CIN-related hospita-
lisation was $13,372 per episode (Caggiano et al., 2005).
The retrospective study at 115 US centres found that the
average length of stay was 11.570.1 days and that the
average cost per FN episode was $19,1107$305 (Kuderer et
al., 2006). Not included in these calculations are the
indirect costs of care for FN, such as the cost associated
with lost or impaired ability to work, and the cost of lost
productivity because of premature death. One US study
estimated that the indirect cost of hospitalisation for FN was
approximately $5000 per episode, mostly due to lost wages
(Cosler et al., 2004).Benefits of prophylactic G-CSF
The use of G-CSF reduces the risk of FN and FN-related
hospitalisation across a broad range of malignancies and
chemotherapy regimens. A meta-analysis of the first
randomised, controlled trials (five trials of filgrastim, three
trials of lenograstim) showed that the prophylactic use of
G-CSF significantly reduced the incidence of FN by 62%
(odds ratio [OR], 0.38; 95% CI, 0.29–0.49; p ¼ 0.001) and
significantly reduced the risk of documented infection by
49% (OR, 0.51; 95% CI, 0.36–0.73, p ¼ 0.001) (Lyman et al.,
2002). The registrational trials of pegfilgrastim, a G-CSF that
can be administered once per chemotherapy cycle, showed
a reduction in the incidence of FN comparable to that of
filgrastim (Holmes et al., 2002; Green et al., 2003).
Part of the impetus for the new guidelines was the
discovery that pegfilgrastim reduces the risk of FN even
when used with a chemotherapy regimen less myelotoxic
than those previously investigated. Vogel et al. (2005)
showed that in patients with breast cancer treated with
docetaxel 100mg/m2 every 3 weeks (a regimen associated
with FN rates of 10–20% in previous clinical trials), the
incidence of FN was 1% in the G-CSF arm versus 17% in
the control arm, a reduction of 94% (po0.001). The use
of anti-infectives and the number of hospitalisations were
also reduced significantly (po0.001 for both). These
observations led to the updated recommendation that
appears in all three sets of new guidelines: adults need
primary prophylaxis with CSFs when the overall risk of
FN is X20%.
The Vogel trial was included in an updated meta-analysis
that also comprised 10 trials of filgrastim and three trials of
lenograstim, collectively involving 3091 patients (Kuderer
et al., 2005). Besides confirming that the use of G-CSF
significantly reduces the risk of FN, the updated meta-
analysis showed that the prophylactic use of G-CSF reduced
the risk of infection-related mortality by 45% (OR, 0.55; 95%
CI, 0.36–0.84, p ¼ 0.005). The patients included in the 14
trials were generally younger and had fewer comorbiditiesthan patients in routine practice, so the benefit of G-CSF
prophylaxis with regard to infection-related mortality may
actually be greater (Lyman, 2005). Finally, the meta-analysis
showed that the use of G-CSF significantly increased the
delivery of full-dose chemotherapy on schedule. The
average RDI in control and G-CSF patients was 88% (95% CI,
86–90%) and 95% (95% CI, 93–96%), respectively (po0.001).
The ability to sustain dose intensity in patients with
responsive and potentially curable malignancies is one
of the most important benefits of prophylactic G-CSF,
especially now that more intensive or dose-dense regi-
mens are being used to prolong disease-free and overall
survival.Creation of evidence-based guidelines for CSF
prophylaxis
Evidence-based medicine has been defined as the
‘‘conscientious, explicit, and judicious use of current best
evidence in making decisions about the care of individual
patients’’ (Sackett et al., 1996). In relation to nursing,
evidence-based practice centres on the premise that making
clinical decisions according to the best evidence, via the
combination of research literature and clinical expertise,
improves the quality of care and the patient’s quality of life
(Oncology Nursing Society, 2006).
Evidence-based guidelines about prophylactic CSF use
provide a scientifically sound basis for determining which
patients should receive growth factor support. The proce-
dure used to develop the EORTC document (Figure 2) is
typical of the usual process for creating national and
international guidelines. The first step was to form an
expert Working Party, which included representatives of
various groups within the EORTC and other oncology groups.
One of the authors of this article (NK) represented the
European Oncology Nursing Society. The Working Party
prospectively defined a number of questions to be ad-
dressed, such as ‘‘Is there evidence that patient-related
factors increase the risk of FN?’’ and ‘‘Is there evidence that
certain chemotherapy regimens increase the risk of FN?’’.
Literature searches were then undertaken to identify
relevant clinical studies. Because more than 5000 studies
were identified, they were evaluated in an hierarchical
fashion; if a question could be answered using a meta-
analysis, no other studies were reviewed, but if not, phase
III studies were reviewed, then phase II studies, and so on
(Aapro et al., 2006).
For each question, the evidence levels used by American
Society of Clinical Oncology (ASCO) (2005) were applied. For
example, evidence obtained from a meta-analysis of multi-
ple well-designed, controlled studies or from a high-power,
randomised, controlled clinical trial was designated level I.
The lowest level, level V, designated evidence obtained
from case reports and clinical examples. Each recommenda-
tion issued in the guidelines was graded according to the
strength of the evidence. For example, Grade A recommen-
dations were supported by level I evidence or consistent
findings from multiple studies of levels II, III, or IV. Grade B
recommendations were supported by consistent findings
from studies of levels II to IV. All of the EORTC recommenda-
tions discussed here were graded A or B.
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Figure 2 Process for developing the European Organisation for
Research and Treatment of Cancer guidelines on granulocyte
colony-stimulating factor (G-CSF) prophylaxis.
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The ASCO guidelines for CSF use were first published in 1994
and have been updated several times, most recently in 2006
(Smith et al., 2006). The NCCN guidelines for CSF use were
developed in 2005; minor revisions were made later in 2005
and in 2006 (Crawford et al., 2006). Expanding on earlier
guidelines for use of CSFs in older adults with cancer
(Repetto et al., 2003), in 2006 EORTC created more general
guidelines that address the use of G-CSF to reduce the
incidence of chemotherapy-induced FN in patients with
lymphomas and solid tumours (Aapro et al., 2006). An
impetus for the creation or revision of guidelines in 2005 and
2006 was the new evidence from the Vogel trial, discussed
above, that the use of G-CSF substantially reduces the
incidence of FN and FN-related hospitalisation, even when
the risk of FN associated with the chemotherapy regimen is
10–20% (Vogel et al., 2005).
Although there are differences in emphasis, the simila-
rities between the guidelines are striking. In particular,
ASCO, EORTC, and NCCN concur that adults need primary
prophylaxis with CSFs when the chemotherapy regimen is
associated with a risk of FN X20%. Table 1 summarises
and compares the recommendations of the three sets ofguidelines regarding primary prophylaxis with CSFs and
examples of such regimens are listed in Table 2. It is
expected that other chemotherapy regimens should also fall
into this category, but because of the biases in reporting
mentioned earlier, the true rate of FN is not known.
Other factors to be considered when determining whether
adult patients need CSF are treatment-related risk factors
(such as the extent of prior chemotherapy), patient-related
factors (such as age and comorbidities), disease-related
factors (such as the type and stage of the cancer),
and treatment intent (curative, prolongation of life, or
symptom control and palliation). The EORTC and NCCN
guidelines recommend giving particular consideration to
these other factors when the chemotherapy regimen
is associated with intermediate risk of FN (10–20%)—if
overall FN is considered to be X20%, primary prophylaxis
with G-CSF is recommended. Table 3 lists common risk
factors for FN.
The oncology nurse’s role in managing CIN
and FN
Nurses have already assumed a key role in addressing
cancer-associated symptoms such as pain and nausea. They
now have an opportunity to apply evidence-based guidelines
to more effectively manage CIN and reduce the incidence of
new or recurrent episodes of FN.
Across tumour types and chemotherapy regimens, the risk
of FN is greatest in the first cycle of chemotherapy
(Crawford et al., 2004b). This finding contradicts the
historical notion that neutropenia is primarily a cumulative
toxicity. Thus, prior to the first cycle of chemotherapy and
every subsequent cycle, oncology nurses and nurse practi-
tioners should assess patients to identify individuals at
higher risk of FN, using means such as a review of medical
histories, physical examinations, and laboratory studies.
Clinicians can use this information to make data-driven
changes to chemotherapy plans, rather than intuitive
changes. During assessments of patient risk of FN, nurses
should give particular attention to the chemotherapy regi-
mens listed in Table 2 and the risk factors listed in Table 3.
A sample algorithm for determining which patients are at
high risk of FN appears in Figure 3, which combines
recommendations from the EORTC and ASCO guidelines.
Other ways for nurses and nurse practitioners to practice
in concordance with the new guidelines are to: Discuss guideline recommendations for any indications for
G-CSF with the prescribing practitioner.
 Administer G-CSF at the recommended dose and sche-
dule, where indicated, beginning in the first cycle of
chemotherapy, as prescribed by the practitioner.
 Record reasons for the use of G-CSF in the patient’s chart.
With each cycle of chemotherapy, oncology nurses should: Document outcomes and response to treatment before
the next cycle of chemotherapy is administered.
 Monitor patients for complications, especially older
patients, who are more likely to become myelosup-
pressed.
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Table 1 Comparison of three sets of guidelines for prophylactic use of CSFs.




 At X20% overall risk of FN
 Receiving dose-dense or dose-
intense chemotherapy that has
survival benefits
 Receiving adjuvant therapy,
potentially curative treatment,
or treatment intended to
prolong survival, or in other
circumstances where
reductions in dose intensity or
density are known to be
associated with poor prognosis
Recommended for patients:
 Receiving a regimen with FN
risk in the range of X20%
 At high risk of FN based on age,




 X65 years with diffuse
aggressive lymphoma treated
with CHOP or more aggressive
regimens
Recommended for patients:




adjuvant therapy, or treatment
expected to prolong survival
and improve QOL
 Receiving a regimen with FN






 Give particular consideration
to the elevated risk of FN in
patients 465 years
 When assessing FN risk,
consider patient-specific risk
factors, the regimen, and
treatment intent
 When using regimens





patients are at high risk, consider
individual patient risk factors and
treatment intent
 Consider CSFs for patients at
intermediate risk (10%–20%) of
FN or other neutropenic event
compromising treatment
 In determining the risk
categorisation, consider the
regimen and patient- and
disease-specific risk factors
(especially age 465 years),
and factors that may
compromise the ability to
deliver full dose




Not addressed Yes Yes
Secondary
prophylaxis
Recommended for patients who
had a neutropenic complication in
a prior cycle of chemotherapy
(without primary prophylaxis), if a
reduced dose might compromise
survival or treatment outcome
Recommended for patients who
had an episode of FN or dose-
limiting neutropenic event during
the previous cycle of
chemotherapy with the same dose
and schedule planned for the
current cycle
Not addressed
Abbreviations: ASCO, American Society of Clinical Oncology; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CSF,
colony-stimulating factor; EORTC, European Organisation for Research and Treatment of Cancer; FN, febrile neutropenia; NCCN,
National Comprehensive Cancer Network; QOL, quality of life.
Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment 19 Remind patients and their families about the potential for
CIN and the need to monitor body temperature and
symptoms.
 Provide patient education focused on reducing risk of
infection during chemotherapy. The practices best sup-
ported by scientific evidence are thorough, frequent hand
washing and drying; consistent and frequent oral care to
prevent oral mucositis; and avoiding exposure to people
with potential symptoms of respiratory infection (Zitella
et al., 2006).Integrating guidelines into oncology nursing
practice
There are a number of compelling reasons for nurses to
integrate the new guidelines about CSF prophylaxis into
oncology practice (Maxwell and Stein, 2006). The evidence-
based approach promotes the practice of healthcare
providers making decisions based on the best available
data, rather than opinion, habits, instinct, or local
standards. Guidelines also promote uniformity of care.
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DD or DDG VAPEC-B
DD or DDG ACVBP
Ovarian cancer Docetaxel
Paclitaxelb
Urothelial cancer Paclitaxel and carboplatin
MVAC
DDG MVAC
Germ cell tumours BOP-VIP-B
VelP
Other TIC (head and neck cancers)
MAID (sarcoma)
Paclitaxel and cisplatin (cervical
cancer)
Abbreviations: AC, doxorubicin and cyclophosphamide; ACE,
doxorubicin, cyclophosphamide, and etoposide; ACVBP, dox-
orubicin or mitoxantrone with cyclophosphamide, vindesine,
and bleomycin; BOP-VIP-B, bleomycin, cisplatin followed by
cisplatin, ifosfamide, etoposide, and bleomycin; CAV, cyclo-
phosphamide, doxorubicin, and vincristine; CHOP-14 7R,
cyclophosphamide, doxorubicin, vincristine, prednisone ad-
ministered every 14 days with or without rituximab; CHOP-21
7R, cyclophosphamide, doxorubicin, vincristine, prednisone
administered every 21 days with or without rituximab; DD,
dose dense; DDG, dose dense regimen supported by primary
prophylactic G-CSF; DHAP, cisplatin, cytarabine, and dex-
amethasone; ESHAP, etoposide, methylprednisolone, cytar-




Previous history of severe neutropenia with
similar chemotherapy
Type of chemotherapy










Poor performance status (ECOG X2)
Poor nutritional status (e.g., low albumin)
Decreased immune function
Comorbidities (COPD, CVD, liver disease,
DM, low baseline haemoglobin)
Laboratory data (hyperglycemia, elevated
alkaline phosphatase, elevated bilirubin)b
Disease-
related
Bone marrow involvement with tumour






Abbreviations: ANC, absolute neutrophil count; COPD,
chronic obstructive pulmonary disease; CVD, cardiovascular
disease; DM, diabetes mellitus; ECOG, Eastern Cooperative
Oncology Group scale.
aAdapted from Crawford et al. (2006).
bLyman et al. (2006).
abine, and cisplatin; FEC, cyclophosphamide, epirubicin, and
fluorouracil; ICE, ifosfamide, carboplatin, and etoposide;
MAID, mesna, doxorubicin, ifosfamide, and dacarbazine;
MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin;
PE, cisplatin and etoposide; TAC, docetaxel, doxorubicin, and
cyclophosphamide; TIC, paclitaxel, ifosfamide, and carbo-
platin; VAPEC-B, vincristine, doxorubicin, prednisolone,
etoposide, cyclophosphamide, and bleomycin; VeIP, vinblas-
tine, ifosfamide, and cisplatin; VICE, vincristine, ifosfamide,
carboplatin, and etoposide; VIG, vinorelbine, ifosfamide, and
gemcitabine.
aAdapted from Aapro et al. (2006). Note: Results may vary
for similar regimens depending on the patient population
studied.
bPatients in the supporting studies had adverse risk factors
and may have been at increased risk of febrile neutropenia.
Table 2. foot note (continued)
N. Kearney, C. Friese20Patients find this reassuring, particularly those who are seen
by many different clinicians within a large healthcare
system. In addition, guidelines give less-experienced health-
care providers a basis for making decisions and can help
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Figure 3 Patient assessment algorithm to determine whether prophylactic use of granulocyte colony-stimulating factor (G-CSF) is
appropriate, based on the 2006 guidelines for G-CSF of the European Organisation for Research and Treatment of Cancer and of the
American Society of Clinical Oncology. FN indicates febrile neutropenia and NHL indicated non-Hodgkin lymphoma: aAapro et al.,
2006 and bSmith et al., 2006.
Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment 21more-experienced clinicians stay up-to-date with the latest
evidence.
The successful implementation of guidelines requires that
stakeholders be identified and engaged early in the process.
To this end, guidelines should be created by a multi-
disciplinary team that includes, at a minimum, one or more
nurses, a physician and, depending on the size of the clinic,
a physician assistant, pharmacist, and administrator. When
members of the team have an opportunity to provide input
into the development of guidelines, they are more likely to
support their integration at the practice (Maxwell and Stein,
2006).
A suggested process for adapting national guidelines into
practice-specific guidelines is outlined in Figure 4 (Maxwell
and Stein, 2006). The first step is to form the multi-
disciplinary team, which should become thoroughly familiar
with the ASCO, EORTC, and NCCN guidelines. The team
should then perform a chart review to obtain baseline dataabout rates of CIN-related dose modification, FN, and FN-
related hospitalisation, infection, and mortality in the
clinic’s own patients. These data will be helpful in
addressing any questions that clinic decision-makers may
have about the need for closer attention to G-CSF
prophylaxis. Next, the team should create tools and
procedures, such as a list of high-risk chemotherapy
regimens, a risk assessment checklist, and/or an algorithm
adapted from Figure 3. The team should discuss the
practice-specific documents and procedures with the phy-
sicians and other decision-makers, with reference to the
baseline data collected in the chart review. It may be useful
to propose a ‘‘pilot study’’ in which the guidelines will be
used for a limited time with a small number of patients and
then be reevaluated.
Once the documents and procedures have been approved,
the team should train all clinic personnel who will be using
them. The emphasis of nurse training should be the nurse’s
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Figure 4 Process for integrating evidence-based guidelines into nursing practice (Maxwell and Stein, 2006). Published in Community
Oncology, volume 3, Maxwell, Stein, Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia:
from paper to clinical practice, 530–536, Copyright Elsevier 2006.
N. Kearney, C. Friese22role in managing CIN and FN, as discussed above. The team
should conduct an ongoing audit of the staff’s use of the
guidelines, by chart review, to correct any misinterpreta-
tions and uncover barriers to implementation. For example,
complaints about lack of time can be addressed by showing
how the new tools and procedures increase efficiency. Audits
can also be useful in documenting improvements in patient
outcomes.Impact of FN risk assessment on patient
outcomes
There is evidence from nurse-driven research that the
implementation of CSF practice guidelines improves patient
outcomes (Donohue, 2006; Doyle, 2006; Maxwell et al.,
2002; Michelson et al., 2002; White and Keehne-Miron, 2002;
White et al., 2005). Although protocols and assessment tools
have differed from centre to centre, a number of teams
have observed significant improvements in patient outcomes
after nurses became involved in evaluating FN risk.
Donohue (2006) reports on a retrospective chart review of
85 adult patients treated with new courses of chemother-
apy, of whom 35 had been evaluated for FN risk in 2003 by a
nurse, nurse practitioner, or physician. The risk factors
considered were chemotherapy regimen with X40% risk of
FN (the standard in 2003 according to ASCO guidelines), age
X70 years with combination chemotherapy, bone marrow
involvement or compromise, open wounds, history of FN,
first-cycle ANC p500/mm3, or serum albumin level p3.5 g/
dL. Patients assessed for FN risk were less likely to develop
FN, be hospitalised for FN, be treated with intravenous
antibiotics, or require chemotherapy dose reductions or
dose delays. The difference was statistically significant for
dose delays (required for 9% of patients evaluated for FN risk
compared with 32% of the comparison group, p ¼ 0.01).
In a similar study, Doyle (2006) used a more detailed
assessment checklist to prospectively evaluate FN risk in 189patients undergoing chemotherapy from October 2004
through September 2005. That group was compared with
155 patients who had been treated from October 2003
through September 2004, without being evaluated for FN
risk. Implementation of the assessment tool significantly
reduced the number of hospitalisations for FN, from 9.7% in
the comparison group to 2.1% in the group evaluated for FN
risk (p ¼ 0.003). The total number of hospital days also
decreased, from 117 to 24, as did the average length of
hospital stay, from 7.8 days to 6 days.
Table 4 summarises the results of these studies and data
reported by three other groups of nurses who assessed
patient outcomes after implementing guidelines for CSF
prophylaxis. These studies all show that simple changes in
practice can improve outcomes.Summary
Despite the benefits of preventing FN and its consequences,
G-CSF may not be considered for all patients receiving
myelosuppressive chemotherapy, for a variety of reasons.
The guidelines recently published by ASCO, EORTC, and
NCCN provide evidence for directing G-CSF treatment, as
well as increased nursing surveillance and additional
education, toward patients who are at greatest risk of FN
and are most likely to benefit. There is striking similarity
between the three sets of guidelines, particularly with
regard to the recommendation that adults need primary
prophylaxis with CSFs when the overall risk of FN is X20%.
It is now well established that G-CSF prophylaxis reduces
the incidence of FN and FN-related hospitalisation, and
high-level evidence indicates that G-CSF reduces infection-
related mortality and the need for chemotherapy dose
modification. Oncology nurses can help improve patient
outcomes by becoming actively involved in identifying
patients who are candidates for prophylactic G-CSF. The
guidelines can be useful in helping oncology nurses initiate
ARTICLE IN PRESS
Table 4 Patient outcomes after implementation of CSF guidelines by nurses.
Authors Type of practice Type of intervention Outcomes





Doyle (2006) Veterans oncology clinic FN risk assessment tool kFN-related hospitalisations
kLength of hospital stays




Michelson et al. (2002) Hospital outpatient clinic CIN management protocol kDose reductions
mRDI
White and Keehne-Miron (2002) Large community oncology clinic CIN management protocol kFN
kDose delays
mRDI
Abbreviations: CIN, chemotherapy-induced neutropenia; CSF, colony-stimulating factor; FN, febrile neutropenia; RDI, relative dose
intensity.
Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment 23discussions within their practices about the value of multi-
disciplinary approaches to preventing FN.
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